Bruker (BRKR) Expected to Announce Quarterly Earnings on Monday

Bruker (NASDAQ:BRKR) is expected to be announcing its Q3 2025 results before the market opens on Monday, November 3rd. Analysts expect the company to announce earnings of $0.33 per share and revenue of $847.4030 million for the quarter. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS.Parties are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Monday, November 3, 2025 at 8:30 AM ET.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings data on Monday, August 4th. The medical research company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.01). Bruker had a net margin of 2.31% and a return on equity of 17.89%. The company had revenue of $797.40 million for the quarter, compared to analyst estimates of $811.17 million. During the same quarter last year, the company earned $0.52 EPS. The business’s revenue was down .4% compared to the same quarter last year. On average, analysts expect Bruker to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Bruker Stock Performance

BRKR opened at $38.94 on Friday. Bruker has a 52-week low of $28.53 and a 52-week high of $64.64. The company has a quick ratio of 0.70, a current ratio of 1.61 and a debt-to-equity ratio of 1.31. The company has a market cap of $5.91 billion, a P/E ratio of 74.89, a price-to-earnings-growth ratio of 5.31 and a beta of 1.20. The firm’s 50-day moving average price is $34.44 and its 200-day moving average price is $36.98.

Bruker Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, October 3rd. Stockholders of record on Tuesday, September 23rd were issued a dividend of $0.05 per share. The ex-dividend date was Tuesday, September 23rd. This represents a $0.20 annualized dividend and a dividend yield of 0.5%. Bruker’s dividend payout ratio is 38.46%.

Wall Street Analysts Forecast Growth

BRKR has been the topic of several recent analyst reports. Citigroup cut their price objective on shares of Bruker from $40.00 to $38.00 and set a “neutral” rating on the stock in a report on Monday, August 4th. Jefferies Financial Group set a $60.00 price objective on shares of Bruker and gave the company a “buy” rating in a report on Monday, August 4th. Weiss Ratings restated a “sell (d+)” rating on shares of Bruker in a report on Wednesday, October 8th. Barclays cut their price objective on shares of Bruker from $43.00 to $40.00 and set an “overweight” rating on the stock in a report on Thursday, October 2nd. Finally, Wells Fargo & Company cut their price target on shares of Bruker from $60.00 to $50.00 and set an “overweight” rating on the stock in a report on Tuesday, August 5th. Five analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Bruker presently has a consensus rating of “Hold” and an average target price of $51.00.

Insiders Place Their Bets

In related news, Director Cynthia M. Friend sold 3,535 shares of the stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $32.25, for a total value of $114,003.75. Following the transaction, the director owned 18,016 shares in the company, valued at approximately $581,016. This represents a 16.40% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 27.30% of the company’s stock.

Institutional Investors Weigh In On Bruker

Hedge funds and other institutional investors have recently made changes to their positions in the company. EverSource Wealth Advisors LLC grew its stake in shares of Bruker by 51.5% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,770 shares of the medical research company’s stock worth $114,000 after purchasing an additional 942 shares during the period. Tower Research Capital LLC TRC grew its stake in shares of Bruker by 56.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,172 shares of the medical research company’s stock worth $172,000 after purchasing an additional 1,497 shares during the period. iSAM Funds UK Ltd acquired a new stake in shares of Bruker during the 2nd quarter worth approximately $217,000. Vident Advisory LLC acquired a new stake in shares of Bruker during the 2nd quarter worth approximately $251,000. Finally, Marshall Wace LLP acquired a new stake in shares of Bruker during the 2nd quarter worth approximately $252,000. Institutional investors and hedge funds own 79.52% of the company’s stock.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.